Cambridge Discovery Park Adds Three New Leases

Cambridge, MA – The Bulfinch Companies, Inc. (Bulfinch), a private, real estate investment, development and management firm, announced it has signed three new leases with Arbor Biotechnologies (Arbor), Kintai Therapeutics (Kintai) and Simcere Innovation, Inc. (Simcere) in Building 400‐500 at Cambridge Discovery Park (CDP), Bulfinch’s life sciences development in Cambridge.

Currently under construction, Building 400‐500 is Bulfinch’s newest addition to CDP adding 283,000sf of Class A lab and office space to the park with a delivery of Q1 2020. These three new leases bring CDP Building 400‐500 to 88% leased with only 32,215sf remaining available on the top sixth floor.

CDP’s Building 400‐500 is a state‐of‐the‐art, LEED Gold registered building, designed by Stantec, and located in a federally designated Economic Opportunity Zone. The six‐story building was topped off in April 2019 and is set to deliver in Q1 2020, with John Moriarty & Associates, Inc. serving as general contractor.

Arbor Biotechnologies will occupy 36,171sf of space on the fifth floor in Building 400‐500. Arbor is an early‐stage company pushing the boundaries of biodiscovery by unlocking nature’s genetic diversity to create transformative products in human health and sustainability. This new, state‐of‐the‐art space in Building 500 will help support the company’s growth.

Kintai Therapeutics has leased a total of 72,296sf on the third and fourth floors of Building 400‐500. Kintai was founded in 2016 by Flagship Labs, the innovation foundry of Flagship Pioneering. The company’s Precision Enteric MedicineTM (PEMTM) discovery and therapeutic platform is based on a deep understanding of the interconnected biology of the microbiome, gut immune system, and enteric nervous system.

Simcere Innovation, Inc will occupy 26,349sf on the second floor of Building 400‐500. Simcere Innovation is focusing on the research and development of life‐changing therapies to our patients using cutting‐edge technology, such as cell and gene therapies.